Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

SYLVANT

&times

Overview

What is SYLVANT?

SYLVANT (siltuximab) is a human-mouse chimeric monoclonal antibody that binds human interleukin-6 (IL-6). SYLVANT is produced by Chinese hamster ovary cells.

SYLVANT is supplied as a sterile, white, preservative free, lyophilized powder in single-use vials.

Each SYLVANT 100 mg single-use vial contains 100 mg siltuximab, 3.7 mg L-histidine (from L-histidine and L-histidine monohydrochloride monohydrate), 0.8 mg polysorbate 80, and 169 mg sucrose.

Each SYLVANT 400 mg single-use vial contains 400 mg siltuximab, 14.9 mg L-histidine (from L-histidine and L-histidine monohydrochloride monohydrate), 3.2 mg polysorbate 80, and 677 mg sucrose.

Following reconstitution with Sterile Water for Injection, USP (per ), the resulting pH is approximately 5.2. The resulting solution contains 20 mg/mL siltuximab to be administered by intravenous infusion following dilution .



What does SYLVANT look like?



What are the available doses of SYLVANT?

SYLVANT (siltuximab) for Injection is available as:

100 mg of lyophilized powder in a single-use vial for intravenous infusion.

400 mg of lyophilized powder in a single-use vial for intravenous infusion.

What should I talk to my health care provider before I take SYLVANT?

How should I use SYLVANT?

SYLVANT is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

SYLVANT 11 mg/kg is given over 1 hour as an intravenous infusion administered every 3 weeks until treatment failure.

Perform hematology laboratory tests prior to each dose of SYLVANT therapy for the first 12 months and every 3 dosing cycles thereafter. If treatment criteria outlined in are not met, consider delaying treatment with SYLVANT. Do not reduce dose.

Do not administer SYLVANT to patients with severe infections until the infection resolves.

Discontinue SYLVANT in patients with severe infusion related reactions, anaphylaxis, severe allergic reactions, or cytokine release syndromes. Do not reinstitute treatment.


What interacts with SYLVANT?

Sorry No Records found


What are the warnings of SYLVANT?

Sorry No Records found


What are the precautions of SYLVANT?

Sorry No Records found


What are the side effects of SYLVANT?

Sorry No records found


What should I look out for while using SYLVANT?

Severe hypersensitivity reaction to siltuximab or any of the excipients in SYLVANT.


What might happen if I take too much SYLVANT?

No case of overdose has been reported.


How should I store and handle SYLVANT?

SYLVANT must be refrigerated at 2°C to 8°C (36°F to 46°F). Do not use SYLVANT beyond the expiration date (EXP) located on the carton and the vial.While stored, protect from light. This product contains no preservative.SYLVANT must be refrigerated at 2°C to 8°C (36°F to 46°F). Do not use SYLVANT beyond the expiration date (EXP) located on the carton and the vial.While stored, protect from light. This product contains no preservative.Nifedipine Extended-Release Tablets are supplied as 30 mg, 60 mg, and 90 mg round film coated tablets. The different strengths can be identified as follows:Nifedipine Extended-Release Tablets are supplied in:The tablets should be protected from light and moisture and stored below 86°F (30°C). Dispense in tight, light-resistant containers (USP). Bayer HealthCare Pharmaceuticals Inc. Wayne, NJ 07470 Rx OnlyNifedipine Extended-Release Tablets are supplied as 30 mg, 60 mg, and 90 mg round film coated tablets. The different strengths can be identified as follows:Nifedipine Extended-Release Tablets are supplied in:The tablets should be protected from light and moisture and stored below 86°F (30°C). Dispense in tight, light-resistant containers (USP). Bayer HealthCare Pharmaceuticals Inc. Wayne, NJ 07470 Rx OnlyNifedipine Extended-Release Tablets are supplied as 30 mg, 60 mg, and 90 mg round film coated tablets. The different strengths can be identified as follows:Nifedipine Extended-Release Tablets are supplied in:The tablets should be protected from light and moisture and stored below 86°F (30°C). Dispense in tight, light-resistant containers (USP). Bayer HealthCare Pharmaceuticals Inc. Wayne, NJ 07470 Rx OnlyNifedipine Extended-Release Tablets are supplied as 30 mg, 60 mg, and 90 mg round film coated tablets. The different strengths can be identified as follows:Nifedipine Extended-Release Tablets are supplied in:The tablets should be protected from light and moisture and stored below 86°F (30°C). Dispense in tight, light-resistant containers (USP). Bayer HealthCare Pharmaceuticals Inc. Wayne, NJ 07470 Rx OnlyNifedipine Extended-Release Tablets are supplied as 30 mg, 60 mg, and 90 mg round film coated tablets. The different strengths can be identified as follows:Nifedipine Extended-Release Tablets are supplied in:The tablets should be protected from light and moisture and stored below 86°F (30°C). Dispense in tight, light-resistant containers (USP). Bayer HealthCare Pharmaceuticals Inc. Wayne, NJ 07470 Rx Only


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Siltuximab binds human IL-6 and prevents the binding of IL-6 to both soluble and membrane-bound IL-6 receptors. IL-6 has been shown to be involved in diverse normal physiologic processes such as induction of immunoglobulin secretion. Overproduction of IL-6 has been linked to systemic manifestations in patients with MCD.

Non-Clinical Toxicology
Severe hypersensitivity reaction to siltuximab or any of the excipients in SYLVANT.

Nifedipine is mainly eliminated by metabolism and is a substrate of CYP3A. Inhibitors and inducers of CYP3A can impact the exposure to nifedipine and consequently its desirable and undesirable effects. and data indicate that nifedipine can inhibit the metabolism of drugs that are substrates of CYP3A, thereby increasing the exposure to other drugs. Nifedipine is a vasodilator, and co-administration of other drugs affecting blood pressure may result in pharmacodynamic interactions.

Do not administer SYLVANT to patients with severe infections until the infection resolves. SYLVANT may mask signs and symptoms of acute inflammation including suppression of fever and of acute Phase reactants such as C-reactive protein (CRP). Monitor patients receiving SYLVANT closely for infections. Institute prompt anti-infective therapy and do not administer further SYLVANT until the infection resolves.

The following adverse reactions are also discussed in other sections of the labeling:

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).